Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 17/20 | 0.69 |
| ▸ | TACR3 | P29371 | 18/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.58 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455845 | 0.87 | TACR2 (0.56) | TACR2TACR3OPRM1KCNH2 | |
| SCHEMBL6851678 | 0.86 | TACR3 (0.69) | TACR2TACR3OPRM1TRPV4KCNH2 | |
| SCHEMBL5437389 | 0.86 | TACR2 (0.84) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL6851699 | 0.85 | TACR3 (0.67) | TACR2TACR3OPRM1KCNH2 | |
| SCHEMBL6854969 | 0.84 | TACR2 (0.63) | TACR2TACR3OPRM1TRPV4KCNH2 | |
| SCHEMBL3962728 | 0.84 | TACR2 (0.79) | TACR2TACR3OPRM1TRPV4KCNH2 | |
| SCHEMBL5422517 | 0.84 | TACR2 (0.53) | TACR2TACR3OPRM1KCNH2 | |
| SCHEMBL27577059 | 0.83 | TACR2 (0.68) | TACR2TACR3OPRM1TRPV4KCNH2 | |
| Hydrochloric Acid SCHEMBL5732533 | 0.83 | TACR2 (0.77) | TACR2TACR3OPRM1TRPV4KCNH2 | |
| SCHEMBL5416281 | 0.83 | TACR2 (0.52) | TACR2TACR3OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377567-B1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2005-12-21 | — | — | EP | claimed |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| EP-1377567-B1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2005-12-21 | — | — | EP | disclosed |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GLAXOSMITHKLINE SPA | 2005-08-11 | — | — | US | disclosed |
| US-20040152726-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-05 | — | — | US | disclosed |
| EP-1377567-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002083663-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152726-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | KCNH2, KCNH3, KCNJ8 | TACR2 56/4885TACR3 149/4885OPRM1 374/4885 |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | KCNQ3, KCNK3, KCNK2 | TACR2 22/4885TACR3 45/4885OPRM1 733/4885 |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNQ3, KCNK3, KCNK2 | TACR2 22/4885TACR3 45/4885OPRM1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.